

<b>Disclaimer</b>	
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arisen from or in reliance upon the whole or any part of the contents of this announcement.	
<b>Cash Dividend Announcement for Equity Issuer</b>	
Issuer name	Sino Biopharmaceutical Limited
Stock code	01177
Multi-counter stock code and currency	Not applicable
Other related stock code(s) and name(s)	Not applicable
Title of announcement	INTERIM DIVIDEND FOR 2023
Announcement date	25 August 2023
Status	New announcement
<b>Information relating to the dividend</b>	
Dividend type	Interim (Semi-annual)
Dividend nature	Ordinary
For the financial year end	Not applicable
Reporting period end for the dividend declared	30 June 2023
Dividend declared	HKD 0.02 per share
Date of shareholders' approval	Not applicable
<b>Information relating to Hong Kong share register</b>	
Default currency and amount in which the dividend will be paid	HKD 0.02 per share
Exchange rate	HKD 1 : HKD 1
Ex-dividend date	04 October 2023
Latest time to lodge transfer documents for registration with share registrar for determining entitlement to the dividend	05 October 2023 16:30
Book close period	From 06 October 2023 to 09 October 2023
Record date	09 October 2023
Payment date	27 October 2023
Share registrar and its address	Tricor Tengis Limited
	17/F, Far East Finance Centre
	16 Harcourt Road
	Hong Kong
<b>Information relating to withholding tax</b>	
Details of withholding tax applied to the dividend declared	Not applicable

<b>Information relating to listed warrants / convertible securities issued by the issuer</b>	
Details of listed warrants / convertible securities issued by the issuer	Not applicable
<b>Other information</b>	
Other information	Not applicable
<b>Directors of the issuer</b>	
The board of directors of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.	